4//SEC Filing
GOLDSMITH MARK A 4
Accession 0001610717-25-000380
CIK 0001628171other
Filed
Nov 13, 7:00 PM ET
Accepted
Nov 14, 8:45 PM ET
Size
12.0 KB
Accession
0001610717-25-000380
Insider Transaction Report
Form 4
GOLDSMITH MARK A
DirectorSee Remarks
Transactions
- Exercise/Conversion
Common Stock
2025-11-12$4.09/sh+20,000$81,800→ 267,863 total - Sale
Common Stock
2025-11-12$65.07/sh−20,000$1,301,410→ 247,863 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-11-12−20,000→ 157,708 totalExercise: $4.09From: 2023-03-13Exp: 2029-03-12→ Common Stock (20,000 underlying)
Holdings
- 70,424(indirect: By Trust)
Common Stock
- 54,498(indirect: By Trust)
Common Stock
- 15,926(indirect: By Trust)
Common Stock
- 570,050(indirect: By Trust)
Common Stock
Footnotes (7)
- [F1]Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on December 19, 2024.
- [F2]Includes 193,475 restricted stock units.
- [F3]This transaction was executed in multiple trades at prices ranging from $65.00 to $65.25. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F4]Held by Jonathan Goldsmith Revocable Trust.
- [F5]Held by Rebecca Goldsmith Revocable Trust.
- [F6]Held by Rebecca Eve Goldsmith Trust under the Goldsmith Children's 2011 Irrevocable Education Trust, dated December 15, 2011.
- [F7]Held by Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust.
Documents
Issuer
Revolution Medicines, Inc.
CIK 0001628171
Entity typeother
Related Parties
1- filerCIK 0001246842
Filing Metadata
- Form type
- 4
- Filed
- Nov 13, 7:00 PM ET
- Accepted
- Nov 14, 8:45 PM ET
- Size
- 12.0 KB